173 related articles for article (PubMed ID: 18360072)
1. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Okamoto K; Nishino T
J Nippon Med Sch; 2008 Feb; 75(1):2-3. PubMed ID: 18360072
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitors of xanthine oxidoreductase].
Okamoto K
Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol.
Okamoto K; Eger BT; Nishino T; Pai EF; Nishino T
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):888-93. PubMed ID: 18600558
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Sato T; Ashizawa N; Matsumoto K; Iwanaga T; Nakamura H; Inoue T; Nagata O
Bioorg Med Chem Lett; 2009 Nov; 19(21):6225-9. PubMed ID: 19783139
[TBL] [Abstract][Full Text] [Related]
6. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
7. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
Matsumoto K; Okamoto K; Ashizawa N; Nishino T
J Pharmacol Exp Ther; 2011 Jan; 336(1):95-103. PubMed ID: 20952484
[TBL] [Abstract][Full Text] [Related]
8. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
9. Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.
Kikuchi H; Fujisaki H; Furuta T; Okamoto K; Leimkühler S; Nishino T
Sci Rep; 2012; 2():331. PubMed ID: 22448318
[TBL] [Abstract][Full Text] [Related]
10. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
Okamoto K; Eger BT; Nishino T; Kondo S; Pai EF; Nishino T
J Biol Chem; 2003 Jan; 278(3):1848-55. PubMed ID: 12421831
[TBL] [Abstract][Full Text] [Related]
11. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
12. Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study.
Pathak RK; Gupta A; Shukla R; Baunthiyal M
Comput Biol Chem; 2018 Oct; 76():32-41. PubMed ID: 29906649
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
[TBL] [Abstract][Full Text] [Related]
14. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
15. Xanthine dehydrogenase electrocatalysis: autocatalysis and novel activity.
Kalimuthu P; Leimkühler S; Bernhardt PV
J Phys Chem B; 2011 Mar; 115(11):2655-62. PubMed ID: 21361328
[TBL] [Abstract][Full Text] [Related]
16. Xanthine Oxidoreductase Inhibitors.
Vickneson K; George J
Handb Exp Pharmacol; 2021; 264():205-228. PubMed ID: 32789757
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Shimo T; Ashizawa N; Matsumoto K; Nakazawa T; Nagata O
Toxicol Sci; 2005 Sep; 87(1):267-76. PubMed ID: 15933230
[TBL] [Abstract][Full Text] [Related]
18. Chemical nature and reaction mechanisms of the molybdenum cofactor of xanthine oxidoreductase.
Okamoto K; Kusano T; Nishino T
Curr Pharm Des; 2013; 19(14):2606-14. PubMed ID: 23116398
[TBL] [Abstract][Full Text] [Related]
19. [New antihyperuricemic medicine: febuxostat, Puricase, etc].
Ichida K
Nihon Rinsho; 2008 Apr; 66(4):759-65. PubMed ID: 18409528
[TBL] [Abstract][Full Text] [Related]
20. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
